Related Experiment Video
Updated: May 28, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
Published on: May 14, 2013
Sirolimus- vs. paclitaxel-eluting stent to coronary intervention in dialysis patients
Daisuke Kamoi1, Hideki Ishii, Hiroshi Takahashi
1Department of Cardiology, Nagoya Kyoritsu Hospital, Nagoya, Japan.
Insights
Sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES) showed similar restenosis rates in hemodialysis patients undergoing percutaneous coronary intervention. Patients on hemodialysis remain at high risk for restenosis despite drug-eluting stent treatment.
Area of Science:
- Cardiology
- Interventional Cardiology
- Nephrology
Background:
- Patients on maintenance hemodialysis (HD) face elevated restenosis risk post-percutaneous coronary intervention (PCI).
- Drug-eluting stents (DES) are used to mitigate this risk, but comparative data in HD patients is limited.
Purpose of the Study:
- To compare the efficacy of sirolimus-eluting stents (SES) versus paclitaxel-eluting stents (PES) in preventing restenosis.
- To evaluate angiographic outcomes in hemodialysis patients with coronary artery disease treated with SES or PES.
Main Methods:
- 100 maintenance hemodialysis patients undergoing PCI were randomized to SES or PES.
- Follow-up angiographic outcomes were assessed at 8 months.
Main Results:
- No significant difference in angiographical restenosis rates between SES (19.7%) and PES (20.0%) groups (p=0.97).
- Similar late loss and no significant differences in major adverse cardiac events or target lesion revascularization between groups.
Conclusions:
- Both SES and PES demonstrate comparable angiographic outcomes in hemodialysis patients at 8-month follow-up.
- Hemodialysis patients remain at high risk for restenosis, even after treatment with current DES.
Background:
Patients on maintenance hemodialysis (HD) are at high risk for restenosis after percutaneous coronary intervention (PCI) even if treated with a sirolimus-eluting stent (SES). The aim of this study was to compare the effects of SES and paclitaxel-eluting stent (PES) in preventing restenosis in HD patients with coronary artery disease.
Methods:
A total of 100 consecutive patients on HD who underwent PCI were enrolled into the study. They were randomly assigned to receive either SES or PES. We compared follow-up angiographic outcomes between the SES and PES groups at 8-month follow-up.
Results:
The angiographical restenosis rate, defined as % diameter stenosis>50% at 8-month follow-up, was 19.7% in the SES group and 20.0% in the PES group (p=0.97). Late loss was also similar between the two groups (0.49±0.70 mm vs. 0.48±0.91 mm, P=0.94). There were no significant differences in the rates of all-cause death, non-fatal myocardial infarction, or TLR due to stent restenosis-induced ischemia between the two groups (2.0% vs. 4.0%, p=0.56, 2.0% vs. 4.0%, p=0.56, and 16.0% vs. 12.0%, p=0.57, respectively).
Conclusions:
There was no significant difference in angiographical outcome at 8-month follow-up between HD patients treated with SES and PES. Even if treated with DES including SES and PES, patients on HD are at high risk of restenosis after PCI.
Related Concept Videos
Extracorporeal Removal of Drugs: Peritoneal Dialysis and Hemodialysis
Hemodialysis II: Procedure and Complications
Peripheral Artery Disease III: Interprofessional Care
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications
Hemodialysis III: Nursing Management

